RXi Pharmaceuticals Corporation (Nasdaq:RXII) announced a clinical trial update on its lead program, NeuVax(TM) (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin(R).
Read full article:http://bestotc.com/18268/stock-alerts/rxii-gblhfpk-prkr-mjgcfpk-snss-stocks-in-action-by-bestotccom/
(RXII, GBLHF.PK, PRKR, MJGCF.PK, SNSS) Stocks in Action by BestOtc.com
September 19th, 2011 at 10:02 am